EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection

Greg Moeck iD, Leanne B Gasink, Rodrigo E Mendes iD, Leah N Woosley iD, MaryBeth Dorr iD, Hongzi Chen iD, Florian M Wagenlehner iD, Tim Henkel iD, Paul C McGovern iD

Antimicrobial Agents and Chemotherapy · 2024

DOI: 10.1128/aac.00236-24 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Greg Moeck und 8 weiteren Autor:innen. Beteiligte Einrichtung: Venatorx Pharmaceuticals, Inc., Malvern, Pennsylvania, USA. Hauptthemen laut MEDLINE: Meropenem, Cefepime, Anti-Bacterial Agents, Urinary Tract Infections. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HHS | Biomedical Advanced Research and Development Authority (BARDA), Venatorx Pharmaceuticals, Inc., Global Antibiotic Research and Development Partnership (GARDP) Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CERTAIN-1 was a Phase 3, double-blind, randomized, parallel group study of the efficacy and safety of cefepime-taniborbactam versus meropenem in the treatment of adults with complicated urinary tract infection (cUTI), including acute pyelonephritis. We determined susceptibility of Enterobacterales and Pseudomonas aeruginosa baseline pathogens to cefepime-taniborbactam and comparators and characterized β-lactam resistance mechanisms. Microbiologic response and clinical response were assessed in patient subsets defined by baseline pathogens that were of cefepime-, multidrug-, or carbapenem-resistant phenotype or that carried β-lactamase genes. Among Enterobacterales baseline pathogens, 26.8%, 4.1%, and 3.0% carried genes for extended-spectrum β-lactamases (ESBLs), AmpC, and carbapenemases, respectively. Within each treatment group, while composite success rates at Test of Cure in resistant subsets by pathogen species were similar to those by pathogen overall, composite success rates in meropenem patients were numerically lower for cefepime-resistant Escherichia coli (9/19; 47.4%) and ESBL E. coli (13/25; 52.0%) compared with E. coli overall (62/100; 62.0%). Cefepime-taniborbactam achieved composite success in 7/8 (87.5%) patients with carbapenem-resistant Enterobacterales and 8/9 (88.9%) patients with Enterobacterales with a carbapenemase gene (5 OXA-48-group; 2 KPC-3; 2 NDM-1). Cefepime-taniborbactam also achieved composite success in 8/16 (50.0%) patients and clinical success in 13/16 (81.3%) patients with P. aeruginosa ; corresponding rates were 4/7 (57.1%) and 6/7 (85.7%) for meropenem. Cefepime-taniborbactam demonstrated efficacy in adult cUTI patients with cefepime-, multidrug-, and carbapenem-resistant pathogens including pathogens with ESBL, AmpC, and carbapenemase genes. CLINICAL TRIALS This study is registered with ClinicalTrials.gov as NCT03840148 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeropenemCefepimeAnti-Bacterial AgentsUrinary Tract InfectionsCephalosporinsMicrobial Sensitivity Testsbeta-LactamasesHumansAdultFemaleMalePseudomonas aeruginosaMiddle AgedDouble-Blind MethodBacterial ProteinsGenotypePhenotypeAgedEscherichia coliTreatment OutcomeBorinic AcidsCarboxylic Acids

Stichwörter der Autor:innen

carbapenemasecefepime-taniborbactamcomplicated urinary tract infectionmeropenemoutcomeβ-lactamase inhibitor

Substanzen

MeropenemCefepimeAnti-Bacterial AgentsCephalosporinsbeta-LactamasestaniborbactamBacterial ProteinscarbapenemaseAmpC beta-lactamasesBorinic Acids

Autor:innen und Institutionen

  • Venatorx Pharmaceuticals, Inc., Malvern, Pennsylvania, USA.
  • LBG Consulting, LLC, Saint Davids, Pennsylvania, USA.
  • JMI Laboratories, North Liberty, Iowa, USA.
  • Justus Liebig University, Giessen, Germany.

ORCID-Profile: Greg Moeck, Rodrigo E Mendes, Leah N Woosley, MaryBeth Dorr, Hongzi Chen, Florian M Wagenlehner, Tim Henkel, Paul C McGovern

Förderung

  • HHS | Biomedical Advanced Research and Development Authority (BARDA)
  • Venatorx Pharmaceuticals, Inc.
  • Global Antibiotic Research and Development Partnership (GARDP) Foundation
  • Everest Medicines

Zitieren

APA

Moeck, G., Gasink, L. B., Mendes, R. E., Woosley, L. N., Dorr, M., Chen, H., Wagenlehner, F. M., Henkel, T., & McGovern, P. C. (2024). Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00236-24

Vancouver

Moeck G, Gasink LB, Mendes RE, Woosley LN, Dorr M, Chen H, et al. Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00236-24

BibTeX
@article{Moeck2024,
  author = {Moeck, Greg and Gasink, Leanne B and Mendes, Rodrigo E and Woosley, Leah N and Dorr, MaryBeth and Chen, Hongzi and Wagenlehner, Florian M and Henkel, Tim and McGovern, Paul C},
  title = {Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  doi = {10.1128/aac.00236-24}
}
Kostenlos starten →